Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors

Headache

Volumn 45, Issue 7, 2005, Pages 850-861

  Jakubowski, Moshe ^a   Levy, Dan ^a   Goor Aryeh, Itay ^a   Collins, Beth ^a   Bajwa, Zahid ^a   Burstein, Rami ^a,b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

Headache; Hyperalgesia; Inflammation; Nociception; Pain; Trigeminal; Triptans

Indexed keywords

ANTIMIGRAINE AGENT; BRADYKININ; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE; INDOMETACIN; KETOROLAC; PROSTAGLANDIN E2; SEROTONIN;

ADOLESCENT; ADULT; ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; HUMAN; INFLAMMATION; MIGRAINE; NERVE CELL; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; SENSITIZATION; TREATMENT OUTCOME; TRIGEMINAL NUCLEUS;

ADOLESCENT; ADULT; ANIMALS; CENTRAL NERVOUS SYSTEM; CYCLOOXYGENASE INHIBITORS; HUMANS; INDOMETHACIN; INFUSIONS, PARENTERAL; KETOROLAC; MIDDLE AGED; MIGRAINE DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN AGONISTS; SKIN; SUMATRIPTAN; TREATMENT OUTCOME;

EID: 22944479617     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2005.05153.x     Document Type: Article

References (42)

1. Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol. 1998;79:964-982.
2. Yamamura H, Malick A, Chamberlin NL, Burstein R. Cardiovascular and neuronal responses to head stimulation reflect central sensitization and cutaneous allodynia in a rat model of migraine. J Neurophysiol. 1999;81:479-493.
3. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47:614-624.
4. Burstein R, Jakubowski M, Collins B. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19-26.
5. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: A race against the development of central sensitization. Ann Neurol. 2004;55:27-36.
6. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons by a 5HT1b1d receptor agonist: implications for migraine therapy with triptans. Proc Natl Acad Sci. 2004;101:4274-4279.
7. Rice AS, Lloyd J, Bullingham RE, O'Sullivan G. Ketorolac penetration into the cerebrospinal fluid of humans. J Clin Anesth. 1993;5:459-462.
8. Zhang J, Rivest S. A functional analysis of EP4 receptor-expressing neurons in mediating the action of prostaglandin E2 within specific nuclei of the brain in response to circulating interleukin-1beta. J Neurochem. 2000;74:2134-2145.
9. Seim MB, March JA, Dunn KA. Intravenous ketorolac vs intravenous prochlorperazine for the treatment of migraine headaches. Acad Emerg Med. 1998;5:573-576.
10. Meredith JT, Wait S, Brewer KL. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med. 2003;21:173-175.
11. Davis CP, Torre PR, Schafer NC, Dave B, Bass B Jr. Ketorolac as a rapid and effective treatment of migraine headache: evaluations by patients. Am J Emerg Med. 1993;11:573-575.
12. Davis CP, Torre PR, Williams C, et al. Ketorolac versus meperidine-plus-promethazine treatment of migraine headache: evaluations by patients. Am J Emerg Med. 1995;13:146-150.
13. Shrestha M, Singh R, Moreden J, Hayes JE. Ketorolac vs chlorpromazine in the treatment of acute migraine without aura. A prospective, randomized, double-blind trial. Arch Intern Med. 1996;156:1725-1728.
14. Klapper JA, Stanton JS. Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches. Headache. 1991;31:523-524.
15. Larkin GL, Prescott JE. A randomized, double-blind, comparative study of the efficacy of ketorolac tromethamine versus meperidine in the treatment of severe migraine. Ann Emerg Med. 1992;21:919-924.
16. Duarte C, Dunaway F, Turner L, Aldag J, Frederick R. Ketorolac versus meperidine and hydroxyzine in the treatment of acute migraine headache: a randomized, prospective, double-blind trial. Ann Emerg Med. 1992;21:1116-1121.
17. Vinson DR. Treatment patterns of isolated benign headache in US emergency departments. Ann Emerg Med. 2002;39:215-222.
18. Headache Classification Committee of the International Headache Society. Classification and diagnosis criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia. 1988;8:1-92.
19. Burstein R, Cutrer FM, Yarnitsky D. The development of cutaneous allodynia during a migraine attack: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000;123:1703-1709.
20. Lindblom U. Analysis of abnormal touch, pain, and temperature sensation in patients. In: Boivie J, Hansson P, Lindblom U, eds. Touch, Temperature and Pain in Health and Disease: Mechanism and Assesments. Seattle: IASP press; 1994: 63-84.
21. Harrison JL, Davis KD. Cold-evoked pain varies with skin type and cooling rate: a psychophysical study in humans. Pain. 1999;83:123-135.
22. Strigo IA, Carli F, Bushnell MC. Effect of ambient temperature on human pain and temperature perception. Anesthesiology. 2000;92:699-707.
23. Levy D, Strassman AM. Mechanical response properties of A and C primary afferent neurons innervating the rat intracranial dura. J Neurophysiol. 2002;88:3021-3031.
24. Steen KH, Steen AE, Kreysel HW, Reeh PW. Inflammatory mediators potentiate pain induced by experimental tissue acidosis. Pain. 1996;66:163-170.
25. Steen KH, Steen AE, Reeh PW. A dominant role of acid pH in inflammatory excitation and sensitization of nociceptors in rat skin, in vitro. J Neurosci. 1995;15(5 Pt 2):3982-3989.
26. Steen KH, Reeh PW, Anton F, Handwerker HO. Protons selectively induce lasting excitation and sensitization to mechanical stimulation of nociceptors in rat skin, in vitro. J Neurosci. 1992;12:86-95.
27. Levy D, Strassman AM. Distinct sensitizing effects of the cAMP-PKA second messenger cascade on rat dural mechanonociceptors. J Physiol. 2002;538(Pt 2):483-493.
28. Siegel S. Nonparametric Statistics for the Behavioral Sciences. Tokyo: McG raw-Hill Kogakusha, 1956.
29. Zar JH. Biostatistical Analysis. 4th ed. Englewood Cliffs: Prentice-Hall, 1998.
30. Ji RR, Befort K, Brenner GJ, Woolf CJ. ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity. J Neurosci. 2002;22:478-485.
31. Samad TA, Moore KA, Sapirstein A, et al. interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature. 2001;410:471-475.
32. Watkins LR, Milligan ED, Maier SF. Spinal cord glia: new players in pain. Pain. 2001;93:201-205.
33. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001;24:450-455.
34. Vanderah TW, Suenaga NM, Ossipov MH, Malan TP, Jr., Lai J, Porreca F. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci. 2001;21:279-286.
35. Vanderah TW, Gardell LR, Burgess SE, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci. 2000;20:7074-7079.
36. Cho HJ, Basbaum AI. Ultrastructural analysis of dynorphin B-immunoreactive cells and terminals in the superficial dorsal horn of the deafferented spinal cord of the rat. J Comp Neurol. 1989;281:193-205.
37. Nahin RL, Hylden JL, Humphrey E. Demonstration of dynorphin A 1-8 immunoreactive axons contacting spinal cord projection neurons in a rat model of peripheral inflammation and hyperalgesia. Pain. 1992;51:135-143.
38. Caudle RM, Isaac L. A novel interaction between dynorphin(1-13) and an N-methyl-D-aspartate site. Brain Res. 1988;443:329-332.
39. Faden AI. Dynorphin increases extracellular levels of excitatory amino acids in the brain through a non-opioid mechanism. J Neurosci. 1992;12:425-429.
40. Arcaya JL, Cano G, Gomez G, Maixner W, Suarez-Roca H. Dynorphin A increases substance P release from trigeminal primary afferent C-fibers. Eur J Pharmacol. 1999;366:27-34.
41. Claude P, Gracia N, Wagner L, Hargreaves KM. Effect of dynorphin on ICGRP release from capsaicin-sensitive fibers. Proceedings of the Ninth World Congress on Pain, 1999.
42. Quadir M, Zia H, Needham TE. Development and evaluation of nasal formulations of ketorolac. Drug Deliv. 2000;7:223-229.